Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
Kymab

Kymab

Kymab is a biopharmecutical company developing human antibody based therapies founded in 2010.

OverviewStructured DataIssuesContributorsActivity

Kymab is a biopharmecutical company founded in 2010. The company was started in parntership by Professor Allan Bradley and Dr Glenn A Friedrich. Kymab is developing human antibody based therapies using embryonic stem cell technology.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery

E Lee, Qi Liang, Hanif Ali, Luke Bayliss, Alastair Beasley, Tara Bloomfield-Gerdes, Laura Bonoli, Richard Brown, Jamie Campbell, Adam Carpenter, Sara Chalk, Alison Davis, Nick England, Alla Fane-Dremucheva, Bettina Franz, Volker Germaschewski, Helen Holmes, Steve Holmes, Ian Kirby, Miha Kosmac, Anais Legent, Hui Lui, Anais Manin, Siobhan O'leary, Jemima Paterson, Rocco Sciarrillo, Anneliese Speak, Dominik Spensberger, Laura Tuffery, Nikole Waddell, Wei Wang, Sophie Wells, Vivian Wong, Andrew Wood, Michael J Owen, Glenn A Friedrich, Allan Bradley

https://www.kymab.com/media/uploads/files/Lee_et_al._2014-1.pdf

Journal

April 4, 2014

References

Find more companies like Kymab

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo